Home › Ovarian Cancer
Ovarian Cancer clinical trials recruiting in the U.S.
269 studies for Ovarian Cancer are recruiting participants at sites across the United States.
Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
Cities with the most studies
- Houston, TX90 studies
- New York City, NY75 studies
- Boston, MA62 studies
- Los Angeles, CA53 studies
- Nashville, TN50 studies
- Arlington, VA47 studies
- Philadelphia, PA47 studies
- Columbus, OH39 studies
- St. Louis, MO37 studies
- Chicago, IL36 studies
- San Antonio, TX33 studies
- Pittsburgh, PA32 studies
- Dallas, TX31 studies
- Queens, NY30 studies
- Atlanta, GA29 studies
- Seattle, WA29 studies
- Cleveland, OH29 studies
- Oklahoma City, OK29 studies
- Durham, NC28 studies
- Portland, OR28 studies
- Detroit, MI28 studies
- Baldwin Park, CA27 studies
- Rochester, MN27 studies
- Washington, DC25 studies
- Grand Rapids, MI25 studies
- Birmingham, AL25 studies
- Orlando, FL24 studies
- San Diego, CA24 studies
- Miami, FL24 studies
- Minneapolis, MN23 studies
- Baltimore, MD23 studies
- Aurora, CO23 studies
- San Francisco, CA20 studies
- New Haven, CT20 studies
- Tampa, FL20 studies
- Fort Worth, TX19 studies
- Mountain View, CA19 studies
- Edison, NJ19 studies
- Salt Lake City, UT19 studies
- Indianapolis, IN18 studies
By state
- Alabama29 studies
- Alaska7 studies
- Arizona25 studies
- Arkansas10 studies
- California109 studies
- Colorado44 studies
- Connecticut27 studies
- Delaware5 studies
- District of Columbia8 studies
- Florida83 studies
- Georgia34 studies
- Hawaii7 studies
- Idaho4 studies
- Illinois48 studies
- Indiana23 studies
- Iowa11 studies
- Kansas12 studies
- Kentucky22 studies
- Louisiana20 studies
- Maine8 studies
- Maryland40 studies
- Massachusetts70 studies
- Michigan51 studies
- Minnesota51 studies
- Mississippi6 studies
- Missouri41 studies
- Montana10 studies
- Nebraska16 studies
- Nevada10 studies
- New Hampshire4 studies
- New Jersey39 studies
- New Mexico14 studies
- New York101 studies
- North Carolina48 studies
- North Dakota7 studies
- Ohio68 studies
- Oklahoma32 studies
- Oregon37 studies
- Pennsylvania73 studies
- Rhode Island16 studies
- South Carolina16 studies
- South Dakota16 studies
- Tennessee56 studies
- Texas128 studies
- Utah30 studies
- Virginia60 studies
- Washington39 studies
- West Virginia11 studies
- Wisconsin30 studies
Recently updated studies
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07360314DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 13, 2026 · NCT06964009Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07001748Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RecruitingObservational study
Ages 2 to 100 · All sexes · Updated Nov 12, 2026 · NCT01950572Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Recruiting
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05649072Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT04847063A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT07664735A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07778498Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT06915025Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05739981A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Nov 12, 2026 · NCT01174121Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT06083844Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT07743164A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06824467A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT07318558Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT07718854Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06580314Phase 1 Study of VT-101 in Advanced Ovarian Cancer
RecruitingPhase 1
Ages 18 to 99 · Women · Updated Nov 9, 2026 · NCT07905677A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 9, 2026 · NCT07546500A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 9, 2026 · NCT04516447Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT07851025Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT06787612A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recruiting
Ages 35 to 50 · Women · Updated Nov 6, 2026 · NCT04251052From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.